Oncological and Functional Outcomes of Elderly Men Treated with HIFU Vs. Minimally Invasive Radical Prostatectomy: A Propensity Score Analysis
Overview
Oncology
Authors
Affiliations
Aim: To assess outcomes of whole gland high-intensity focused ultrasound (HIFU) as compared with minimally-invasive radical prostatectomy (MIRP) in elderly patients.
Materials & Methods: Patients aged ≥70 years with, cT1-cT2 disease, biopsy Gleason score (GS) 3 + 3 or 3 + 4 and preoperative PSA ≤10 ng/mL were submitted to either whole-gland HIFU or MIRP. Propensity-score matching analysis was performed to ensure the baseline equivalence of groups. Follow-up visits were routinely performed assessing PSA and urinary function according to the International Continence Score (ICS) and the International Prostatic Symptoms Score (IPSS) questionnaires. Estimated rates of salvage-treatment free survival (SFS) overall-survival (OS), cancer-specific survival (CSS) and metastasis-free survival (MTS) were assessed and compared.
Results: Overall, 84 (33.3%) and 168 (66.7%) patients were treated with HIFU and MIRP, respectively. MIRP was associated with a 5-yrs SFS of 93.4% compared to 74.8% for HIFU (p < 0.01). The two groups did not differ in terms of OS and MTS. No cancer-related deaths were registered. Patients treated with HIFU showed better short-term (6-mos) continence outcomes [mean-ICS: 1.7 vs. 4.8; p = 0.005] but higher IPSS mean scores at 12-mos assessment. A comparable rate of patients experiencing post-treatment Clavien-Dindo grade ≥III complications was observed within the two groups.
Conclusions: Whole-gland HIFU is a feasible treatment in elderly men with low-to intermediate-risk PCa and could be considered for patients either unfit for surgery, or willing a non-invasive treatment with a low morbidity burden, although a non-negligible risk of requiring subsequent treatment for recurrence should be expected.
Focal Therapy for Prostate Cancer: Recent Advances and Insights.
Lasorsa F, Biasatti A, Orsini A, Bignante G, Farah G, Pandolfo S Curr Oncol. 2025; 32(1).
PMID: 39851931 PMC: 11764426. DOI: 10.3390/curroncol32010015.
Pan Y, Wang S, Liu L, Liu X Front Oncol. 2022; 12:988490.
PMID: 36313706 PMC: 9597449. DOI: 10.3389/fonc.2022.988490.
He Y, Tan P, He M, Hu L, Ai J, Yang L Medicine (Baltimore). 2020; 99(41):e22610.
PMID: 33031318 PMC: 7544371. DOI: 10.1097/MD.0000000000022610.
Thompson J, Sridhar A, Shaw G, Rajan P, Mohammed A, Briggs T BMC Urol. 2020; 20(1):81.
PMID: 32611411 PMC: 7329479. DOI: 10.1186/s12894-020-00656-9.
Rosenhammer B, Ganzer R, Zeman F, Nager T, Fritsche H, Blana A World J Urol. 2019; 37(10):2073-2080.
PMID: 30603784 DOI: 10.1007/s00345-018-2613-z.